Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-2752 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm A: mRNA-2752 | EXPERIMENTAL | Participants will be administered mRNA-2752 at an applicable dose as monotherapy. |
| Arm B: mRNA-2752 + Durvalumab | EXPERIMENTAL | Participants will be administered mRNA-2752 at an applicable dose in combination with durvalumab. |
| Arm C: mRNA-2752 Alone or mRNA-2752 + Durvalumab | EXPERIMENTAL | Participants will be administered mRNA-2752 at an applicable dose as monotherapy or in combination with durvalumab. |
| Name | Type | Description |
|---|---|---|
| mRNA-2752 | BIOLOGICAL | Solution for intratumoral injection |
| Durvalumab | BIOLOGICAL | Solution for infusion after dilution |
Inclusion Criteria: * Written informed consent prior to completing any study-specific procedure * Histologically confirmed advanced or metastatic disease with at least 1 measurable lesion as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Cheson 2016 criteria * Do...
mRNA-2752 is an investigational oncology therapy being studied for the treatment of relapsed or refractory solid tumor malignancies or lymphoma. It is administered by intratumoral injection and is currently in Phase 1 clinical development.
mRNA-2752 is being developed by Moderna, Inc., a biotechnology company traded on the Nasdaq under the ticker symbol MRNA. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy.
mRNA-2752 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under clinical investigation.
mRNA-2752 has one completed clinical trial, NCT03739931, a Phase 1 dose escalation study for intratumoral injection in participants with advanced malignancies. The trial enrolled 134 participants across the United States, Australia, and Israel.
mRNA-2752 is a distinct investigational drug candidate developed by Moderna. No alternative names have been reported for this asset in the available clinical trial information.